DMTK has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
DMTK has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Operating Margin % is calculated as Operating Income divided by its Revenue. DermTech's Operating Income for the three months ended in Mar. 2024 was $-20.51 Mil. DermTech's Revenue for the three months ended in Mar. 2024 was $3.85 Mil. Therefore, DermTech's Operating Margin % for the quarter that ended in Mar. 2024 was -533.37%.
The historical rank and industry rank for DermTech's Operating Margin % or its related term are showing as below:
DermTech's 5-Year Average Operating Margin % Growth Rate was 0.00% per year.
DermTech's Operating Income for the three months ended in Mar. 2024 was $-20.51 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Mar. 2024 was $-92.20 Mil.
The historical data trend for DermTech's Operating Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DermTech Annual Data | |||||||||||||||||
Trend | Mar16 | Mar17 | Mar18 | Mar19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||
Operating Margin % | Get a 7-Day Free Trial | - | -599.64 | -653.81 | -813.92 | -678.21 |
DermTech Quarterly Data | ||||||||||||||||||||
Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
Operating Margin % | Get a 7-Day Free Trial | -921.63 | -807.34 | -506.00 | -503.36 | -533.37 |
For the Diagnostics & Research subindustry, DermTech's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Medical Diagnostics & Research industry and Healthcare sector, DermTech's Operating Margin % distribution charts can be found below:
* The bar in red indicates where DermTech's Operating Margin % falls into.
Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.
DermTech's Operating Margin % for the fiscal year that ended in Dec. 2023 is calculated as
Operating Margin % | = | Operating Income (A: Dec. 2023 ) | / | Revenue (A: Dec. 2023 ) |
= | -103.739 | / | 15.296 | |
= | -678.21 % |
DermTech's Operating Margin % for the quarter that ended in Mar. 2024 is calculated as
Operating Margin % | = | Operating Income (Q: Mar. 2024 ) | / | Revenue (Q: Mar. 2024 ) |
= | -20.508 | / | 3.845 | |
= | -533.37 % |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DermTech (NAS:DMTK) Operating Margin % Explanation
Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.
Be Aware
Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).
If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.
For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokias Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).
Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.
Thank you for viewing the detailed overview of DermTech's Operating Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.
Kevin M Sun | officer: Chief Financial Officer | 6340 SEQUENCE DRIVE, SAN DIEGO CA 92121 |
Claudia Ibarra | officer: Chief Operating Officer | C/O DERMTECH, INC., 11099 N. TORREY PINES ROAD, SUITE 100, LA JOLLA CA 92037 |
Ramin Akhavan | officer: General Counsel | C/O DERMTECH, INC., 11099 N. TORREY PINES ROAD, SUITE 100, LA JOLLA CA 92037 |
Mark Bryan Aguillard | officer: Chief Commercial Officer | 19800 CORDILL LANE, SPICEWOOD TX 78669 |
Todd Michael Wood | officer: Chief Commercial Officer | C/O OBALON THERAPEUTICS, INC., 5421 AVENIDA ENCINAS, SUITE F, SAN DIEGO CA 92008 |
Bret Christensen | director, officer: Chief Executive Officer | 600 TECHNOLOGY PARK DRIVE, SUITE 200, BILLERICA MA 01821 |
John Dobak | director, officer: Chief Executive Officer | 11099 N. TORREY PINES ROAD, SUITE 100, LA JOLLA CA 92037 |
Rtw Investments, Lp | 10 percent owner | 40 10TH AVENUE, 7TH FLOOR, NEW YORK NY 10014 |
Kirk Malloy | director | 5200 ILLUMINA WAY, SAN DIEGO CA 92122 |
Mark Christopher Capone | director | 320 WAKARA WAY, SALT LAKE CITY UT 84108 |
Herm Rosenman | director | OXFORD IMMUNOTEC GLOBAL PLC, 94C INNOVATION DRIVE, HILTON PARK, SAN DIEGO X0 OX14 4RZ |
Nathalie Gerschtein Keraudy | director | C/O DERMTECH, INC., 11099 N. TORREY PINES ROAD, SUITE 100, LA JOLLA CA 92037 |
Monica Tellado | director | C/O DERMTECH, INC., 11099 N. TORREY PINES ROAD, SUITE 100, LA JOLLA CA 92037 |
Enrico Picozza | director | 11099 N. TORREY PINES ROAD, SUITE 100, LA JOLLA CA 92037 |
Matthew L. Posard | director | 11099 N. TORREY PINES ROAD, SUITE 100, LA JOLLA CA 92037 |
From GuruFocus
By Business Wire • 12-13-2023
By PRNewswire • 11-17-2023
By PRNewswire • 11-27-2023
By PRNewswire • 12-06-2023
By PRNewswire • 11-21-2023
By PRNewswire • 11-28-2023
By Business Wire • 12-14-2023
By PRNewswire • 12-04-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.